EU’s Covid vaccination debacle is down to institutional inflexibility

Supply delays underline there was no legal or economic justification for central planning

A storm is raging over the EU’s failure to have ordered more of the approved Covid-19 vaccines ahead of time. Stéphane Bancel, the chief executive of the US pharmaceutical company Moderna, which gained approval for its vaccine shortly after Pfizer/BioNTech, claims that the EU has relied too much on “vaccines from its own laboratories”.

Did the European commission prioritise supporting its own pharmaceutical industry over protecting human lives? In fact, matters are not as simple as that. Contrary to what Bancel wants us to believe, the EU has actually ordered too little of its own vaccine. After all, the vaccine that is being administered most widely across the west was developed by a German company, BioNTech, and thus comes from the EU (though it was tested and partly produced in partnership with Pfizer in the US and with Fosun Pharma in China).

Continue reading...

Australia’s chief medical officer defends AstraZeneca’s Covid vaccine amid efficacy concerns

Australia has secured 54m doses of the vaccine some experts say is inferior to Pfizer’s mRNA vaccine, which Australia has bought just 10m doses of

  • Covid hotspots Victoria; NSW hotspots; Queensland hotspots
  • NSW and Sydney trend map: where cases are rising or falling
  • Follow the Australia coronavirus live blog
  • Australia’s chief medical officer, Prof Paul Kelly, and infectious diseases experts have defended securing 54m doses of a Covid-19 vaccine made by Oxford University and the pharmaceutical company AstraZeneca, amid concerns the vaccine will not be effective enough to achieve herd immunity.

    The president of the Australian and New Zealand Society for Immunology, Prof Stephen Turner, told Nine media that Australia should halt the AstraZeneca vaccine rollout because it has “lower efficacy”.

    Continue reading...

    Analysis: is it wise for England to mix and match Covid vaccines?

    US experts warn against plan to give different second jab if supplies run low

    The UK is setting the pace around the world in the approval and use of Covid vaccines but, while other countries watch intently, not all are yet prepared to embrace what looks like public health pragmatism rather than strict adherence to evidence.

    Britain is the first country in the world to approve and use the Oxford/AstraZeneca vaccine, just as it was first with Pfizer/BioNTech’s. In a further trailblazing decision, it is giving everyone a first shot of either of those vaccines, with the second shot delayed to 12 weeks afterwards instead of the three- or four-week interval in the trials.

    Continue reading...

    How is the Oxford Covid vaccine being deployed in England?

    With jab to be administered to public for first time, we look at key questions about its rollout

    The biggest vaccination programme in the UK’s history will receive a major boost on Monday, with the first use of the Oxford/AstraZeneca Covid vaccine. Here we look at some key questions about how it will be deployed in England.

    Continue reading...

    What difference will Oxford/AstraZeneca vaccine make in UK?

    We look at how the introduction of a new vaccine in the fight against Covid will work

    The Oxford/AstraZeneca vaccine is central to the government’s plans for ending social distancing in the UK and returning to some sort of normality. It has invested in seven different vaccines, but the biggest order is for 100m doses of the AstraZeneca jab, most of which will be manufactured in the UK. While the prime minister was jubilant that the UK was first in the world to approve the Pfizer/BioNTech vaccine, he is now able to claim a British triumph. More to the point is the ease of use of the AstraZeneca vaccine. Unlike Pfizer’s, it does not have to be kept in the long term at -70C. Pfizer’s vaccine can be stored in a fridge for five days, but AstraZeneca’s can be kept for months at fridge temperature, which is 2-8C and will be easy to take to care homes to administer to residents, the first priority group for vaccination.

    Continue reading...

    BioNTech criticises EU failure to order enough Covid vaccine

    Firm races to fill potential gap left by bloc’s gamble on several vaccines being approved

    BioNtech has criticised the EU’s failure to order more doses of its coronavirus vaccine, saying it is now racing with its US partner, Pfizer, to boost production amid fears of a European “gap” left by the lack of other approved vaccines.

    The Pfizer/BioNTech vaccine was the first to be approved by the bloc late last month, after being accepted by the UK, Canada and the US. They and other countries have also since approved the Moderna or Oxford/AstraZeneca vaccine, leaving the EU trailing behind.

    Continue reading...

    Questions hang over UK’s rollout of Oxford/AstraZeneca jab

    Analysis: regulator surprises by approving 12-week gap between first and second shots of vaccine as well as Pfizer/BioNTech shot

    It’s a pragmatic solution to an incredibly urgent problem – how to immunise very large numbers of people at risk from a rampaging variant of Covid-19 in the shortest possible time. The answer that government advisers have come up with is to give them all – more than 20 million of them – a single shot of the Oxford/AstraZeneca vaccine so that they have some protection and postpone the second dose to three months afterwards, when hopefully there will be plenty of vaccine available for boosters.

    Related: How well does the Oxford vaccine work? What we know so far

    Continue reading...

    UK scientists trial drug to prevent infection that leads to Covid

    Exclusive: Antibody therapy could confer instant immunity to Covid-19 on at-risk groups

    British scientists are trialling a new drug that could prevent someone who has been exposed to coronavirus from going on to develop the disease Covid-19, which experts say could save many lives.

    The antibody therapy would confer instant immunity against the disease and could be given as an emergency treatment to hospital inpatients and care home residents to help contain outbreaks.

    Continue reading...

    BioNTech vaccine ‘highly likely’ to work against new Covid variant, says chief executive – video

    The chief executive of the German pharmaceutical company BioNTech said he was confident its coronavirus vaccine worked against the new UK variant, but that further studies were needed to be certain. 'Scientifically, it is highly likely that the immune response by this vaccine also can deal with the new virus variants,' Uğur Şahin said. If the vaccine needs to be adjusted for the new variant, the company could do that in about six weeks, he added

    Continue reading...

    Belgian minister tweets EU’s Covid vaccine price list to anger of manufacturers

    Pharmaceutical companies complain of breach of confidentiality after amount EU has agreed to pay for leading vaccines goes public

    A Belgian minister has blown the lid off a sensitive and commercial secret – the price that the EU has agreed to pay for the leading Covid vaccines.

    Belgium’s budget state secretary, Eva De Bleeker, posted the price list on Twitter, with the amounts of each vaccine that her country intends to buy from the EU. The tweet was quickly deleted, but not soon enough to prevent interested parties taking screenshots, which have now made it public knowledge.

    Continue reading...

    British American Tobacco wins approval to test Covid vaccine on humans

    Treatment grown on tobacco plants gets US backing for clinical study

    British American Tobacco has moved a step closer to producing a vaccine for coronavirus using tobacco plants, as it won approval in the US to begin testing on humans.

    The company behind cigarette brands including Lucky Strike, Rothmans and Benson & Hedges said the US Food & Drug Administration had given it clearance to begin a clinical study with adult volunteers.

    Continue reading...

    Covid vaccine arrives in UK hospitals ready for first jabs

    Medical director warns of great hurdles in largest vaccination campaign in UK history

    Batches of the Covid vaccine have begun to arrive in hospitals around the UK, ready for the first jabs on Tuesday in what NHS England’s medical director warned would be the largest and most complex vaccination campaign in the country’s history.

    The UK’s record-breaking approval of the vaccine and the rapid start of immunisation against Covid-19 did not mean the end of the pandemic was in sight, said Prof Stephen Powis. It would be a marathon and not a sprint, he said.

    Continue reading...

    The vaccine miracle: how scientists waged the battle against Covid-19

    We trace the extraordinary research effort, from the discovery of the virus’s structure to the start of inoculations this week

    In the early afternoon of 3 January this year, a small metal box was delivered to the Shanghai Public Health Clinical Centre addressed to virus expert Prof Zhang Yongzhen. Inside, packed in dry ice, were swabs from a patient who was suffering from a novel, occasionally fatal respiratory illness that was sweeping the city of Wuhan. Exactly what was causing terrifying rises in case numbers, medical authorities wanted to know? And how was the disease being spread?

    Related: ‘I worked so hard in the lab. I cried when the news came’

    Continue reading...

    Will everyone in the world have access to a Covid vaccine? – video explainer

    The hunt for a coronavirus vaccine is showing promise but it is premature to say the end of the pandemic is nigh. Several rich countries have signed a 'frenzy of deals' that could prevent many poor nations from getting access to immunisation until at least 2024. Also, many drug firms are potentially refusing to waive patents and other intellectual property rights in order to secure exclusive rights to any cure.

    Michael Safi, the Guardian's international correspondent, explains why 'vaccine nationalisation' could scupper global efforts to kill the virus and examines what is being done to tackle the issue

    Continue reading...

    Different age groups may get different Covid vaccines, experts say

    Oxford/AstraZeneca planning new trial of lower-dose jab to see how well it works in older people

    Concerns around the efficacy of the Oxford University/AstraZeneca coronavirus jab in older people could lead to different age groups being given different vaccines, experts have said.

    The partners announced last week that the vaccine had a 70% efficacy overall. For most trial participants – given two full doses, spaced a month apart – the efficacy was 62%, but for 3,000 participants mistakenly given half a dose for their first jab, the efficacy was 90%. No participants, regardless of dosing, developed severe Covid or were hospitalised with the disease.

    Continue reading...

    A vaccine revolution | podcast

    Results from clinical trials have shown that the world has three apparently highly effective vaccines for Covid-19. With the race now on for regulatory approval, production and distribution, is the end of the pandemic within reach?

    After a gruelling year of successive waves of Covid-19 infections and national lockdowns there has been a burst of good news this month, with three separate vaccine candidates performing extremely well in clinical trials.

    First, Pfizer and Moderna announced that their vaccines were testing at an efficacy of around 95%. Then came the news that the AstraZeneca vaccine (the one pre-ordered in bulk by the UK government) was hitting 90%. It marks not just a new phase in the Covid-19 pandemic but potentially a revolution in vaccine technology itself.

    Continue reading...

    Vaccine results bring us a step closer to ending Covid, says Oxford scientist

    Latest breakthrough comes as PM says he hopes most at-risk could be immunised by Easter

    The world is moving a step closer to ending the coronavirus pandemic, the scientist behind Britain’s first vaccine has declared, as Boris Johnson said he hoped the majority of those most at-risk could be immunised by Easter.

    Successful trial results for the Oxford University/AstraZeneca vaccine, suggesting it could protect up to 90% of people, are the third set of promising findings in as many weeks. Before this year, there had never been a vaccine for a coronavirus.

    Continue reading...

    Oxford AstraZeneca vaccine to be sold to developing countries at cost price

    Jab that is part of global initiative to distribute doses will remain at low price ‘in perpetuity’

    The coronavirus vaccine produced by Oxford University and AstraZeneca will be available on a non-profit basis “in perpetuity” to low- and middle-income countries in the developing world.

    The details of arrangements to supply poorer countries came as AstraZeneca revealed the interim results of a phase 3 trial of the vaccine, which is being heralded as the first to meet the more challenging requirements of the developing world.

    Continue reading...

    Is this the beginning of an mRNA vaccine revolution? | Adam Finn

    No one knew whether mRNA technology would work against this virus – but it does. It’s an extraordinary moment for science

    The past few months have brought a number of scientific terms to public attention. We’ve had to digest R (a virus’s reproduction number) and PCR (the polymerase chain reaction method of testing). And now there’s mRNA. This last one has featured heavily in recent news reports because of the spectacular results of two new mRNA vaccines against coronavirus. It stands for “messenger ribonucleic acid”, a label familiar enough if you studied biology at O-level or GCSE, but otherwise hardly a household name. Even in the field of vaccine research, if you had said as recently as 10 years ago that you could protect people from infections by injecting them with mRNA, you would have provoked some puzzled looks.

    Essentially, mRNA is a molecule used by living cells to turn the gene sequences in DNA into the proteins that are the building blocks of all their fundamental structures. A segment of DNA gets copied (“transcribed”) into a piece of mRNA, which in turn gets “read” by the cell’s tools for synthesising proteins. In the case of an mRNA vaccine, the virus’s mRNA is injected into the muscle, and our own cells then read it and synthesise the viral protein. The immune system reacts to these proteins – which can’t by themselves cause disease – just as if they’d been carried in on the whole virus. This generates a protective response that, we hope, lasts for some time. It’s so beautifully simple it almost seems like science fiction. But last week we learned that it was true.

    Continue reading...

    Hopes of Covid vaccine for more than 1bn people by end of 2021

    Moderna becomes second firm to reveal positive results with nearly 95% protection in trials

    More than 1 billion people could be immunised against coronavirus by the end of next year with shots from the first two companies to reveal positive results, after the latest vaccine was shown to be nearly 95% effective in trials.

    With the US’s top infectious diseases official, Anthony Fauci, hailing “the light at the end of the tunnel”, the US biotech firm Moderna announced impressive results for its mRNA vaccine on Monday, a week after interim results for a Pfizer/BioNTech vaccine showed 90% effectiveness.

    Continue reading...